​

COMPASS Pathways Stock (NASDAQ:CMPS)

ForecastOwnershipFinancialsChartTranscripts
COMPASS Pathways by TradingView

Previous Close

$11.35

52W Range

$3.97 - $15.40

50D Avg

$12.45

200D Avg

$8.23

Market Cap

$1.52B

Avg Vol (3M)

$4.04M

Beta

2.49

Div Yield

-

CMPS Company Profile

COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

GB

Employees

156

IPO Date

Sep 18, 2020

Website

CMPS Performance

CMPS Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-179.04M$-178.21M$-136.92M
Net Income$-287.86M$-155.12M$-118.46M
EBITDA$-179.04M$-148.82M$-115.24M
Basic EPS$-3.08$-2.30$-2.32
Diluted EPS$-3.08$-2.30$-2.32

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q1 26May 13, 26 | 12:00 AM
Q3 25Nov 04, 25 | 8:00 AM
Q2 25Jul 31, 25 | 8:00 PM

Peer Comparison

TickerCompany
GOSSGossamer Bio, Inc.
CYHCommunity Health Systems, Inc.
PRTAProthena Corporation plc
FDMT4D Molecular Therapeutics, Inc.
SNDASonida Senior Living, Inc.
AVNSAvanos Medical, Inc.
VREXVarex Imaging Corporation
TALKTalkspace, Inc.